Topic: mergers and acquisitions
The takeover gives Novo control of a platform that could support development of insulins that respond to glucose.
The takeover agreement comes one year after Vernalis was left reeling by a second FDA rejection in quick succession.
Millendo Therapeutics plans to absorb the floundering, publicly traded OvaScience to support its endocrine-based orphan disease efforts.
Boston Scientific is acquiring the remainder of Veniti for $108 million upfront, plus up to $52 million pending approval of its Vici venous stent.
Premier Research, a global CRO, acquired Regulatory Professionals and will merge the firm into a new division.
Clinical research helper WIRB-Copernicus Group has acquired KMR Group and Metrics Consortium to bolster its market insights and intelligence division.
Amplifon is acquiring hearing care retailer Gaes Group, gaining a foothold in Spain, the tenth largest hearing aid retail market worldwide.
Boston Scientific plans to buy Claret Medical for $220 million upfront, including its safety-net device that catches debris from TAVR procedures.
The deal gives PTC ownership of a gene therapy treatment for rare neurotransmitter disease AADC deficiency that is set to go before the FDA next year.
U.K.-based CRO Clinigen has bought the rights to Novartis’ Proleukin (aldesleukin) outside the U.S. as it looks to boost sales.